Use the hyperlinks, where available to access additional clinical trial information.
A Phase II, Open-Label, Single Arm Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Twenty eligible patients, with relapsed or refractory Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation, will receive a combination of ibrutinib and Tisagenlecleucel treatment in this trial.